Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques

Abstract Developing an intervention that results in virologic control following discontinuation of antiretroviral therapy (ART) is a major objective of HIV-1 cure research. In this study, we investigated the therapeutic efficacy of a vaccine consisting of adenovirus serotype 26 (Ad26) and modified v...

תיאור מלא

מידע ביבליוגרפי
Main Authors: John D. Ventura, Joseph P. Nkolola, Abishek Chandrashekar, Erica N. Borducchi, Jinyan Liu, Noe B. Mercado, David L. Hope, Victoria M. Giffin, Katherine McMahan, Romas Geleziunas, Jeffrey P. Murry, Yunling Yang, Mark G. Lewis, Maria G. Pau, Frank Wegmann, Hanneke Schuitemaker, Emily J. Fray, Mithra R. Kumar, Janet D. Siliciano, Robert F. Siliciano, Merlin L. Robb, Nelson L. Michael, Dan H. Barouch
פורמט: Article
שפה:English
יצא לאור: Nature Portfolio 2022-05-01
סדרה:npj Vaccines
גישה מקוונת:https://doi.org/10.1038/s41541-022-00477-x